Naia Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Naia Pharmaceuticals, Inc.
The numerous different targets of investigational drugs for the treatment of NASH suggest the jury is still out on which mechanism of action is most likely to prove effective against the condition. Ireland’s Afimmune is the latest company wanting to advance an investigational drug for the disorder into late-stage clinical studies.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
In Q1 2015 start-ups raised $2.74 billion, a new record. Biopharma companies penned 37 alliances; 13 start-ups were acquired across all industries.
The diabetes market presents competitive, commercial, and regulatory challenges, but its size and breadth spur emerging biotechs to develop an ever-wider range of treatments and technologies.
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- 9 Meters Biopharma, Inc.
- Innovate Biopharmaceuticals, Inc.
- Naia Metabolic
- Naia Rare Diseases, Inc.
- RDD Pharma Ltd